Tag: Istradefylline

Approved by the FDA in 2019, istradefylline (brand name Nourianz) is the first-in-class, non-dopaminergic medication used as an adjunctive treatment for adult patients with Parkinson's disease who experience 'off' episodes. It works alongside levodopa/carbidopa to manage the motor fluctuations associated with the disease.

Up to 50% of people with Parkinson's disease (PD) who take levodopa/carbidopa begin to experience 'off' episodes within five years of starting treatment, signifying a return of symptoms. The medication Nourianz was approved by the FDA in 2019 specifically to help manage these motor fluctuations. This article explains **what does nourianz do** and how it offers a unique approach to managing Parkinson's symptoms.